Quantcast

Latest SLE Stories

2014-08-12 11:10:06

Wiley Readmissions more likely in black and Hispanic systemic lupus erythematosus patients A new study reveals that one in six patients with systemic lupus erythematosus (SLE) is readmitted to the hospital within 30 days of being discharged. Results published in Arthritis & Rheumatology, a journal of the American College of Rheumatology (ACR), show that black and Hispanic SLE patients were more likely to be readmitted than white patients. Readmissions among patients insured by...

2014-07-16 08:28:09

--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE). http://photos.prnewswire.com/prnvar/20140715/127341 Following the successful completion of it phase 1 single dose safety study with RSLV-132, Resolve recently initiated a phase 2 study in lupus patients. The...

2014-07-07 11:39:51

European League Against Rheumatism Slower dose tapering and absence of positive serology reduce risk of flare A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that, for the majority of lupus patients who are in remission, it is possible to successfully stop immunosuppressant therapy without triggering a flare of their disease. Within two years, it was possible to stop the immunosuppressant in about 70% of clinically stable...

2014-05-13 08:31:54

SHENZHEN, China, May 13, 2014 /PRNewswire/ -- Chinese researchers have recently published new findings in Arthritis Research & Therapy, a top peer-reviewed journal in the field of systemic autoimmune rheumatic diseases, regarding the safety and effectiveness of umbilical cord (UC) derived mesenchymal stem cells (MSCs) in treating 40 patients with severe and refractory Systemic Lupus Erythematosus (SLE). The recent forty patient multi-center study was undertaken to assess the...

2014-05-05 08:30:03

- Significant clinical response to Acthar was observed in patients experiencing active disease while on conventional SLE maintenance therapies - ANAHEIM, Calif., May 5, 2014 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from the first modern clinical study examining the use of H.P. Acthar® Gel (repository corticotropin injection) in systemic lupus erythematosus (SLE) has been published in the journal LUPUS. This independent investigator-initiated...

2014-04-28 23:03:54

According to a new report from BCC Research, the global market for drugs to treat systemic lupus erythematosus (SLE), is expected to grow to $2.6 billion by 2018, with a five-year compound annual growth rate (CAGR) of 22.4%. The North American market, the fastest growing regional segment overall, is growing at a tremendous 24.7% CAGR. Wellesley, Mass., (PRWEB) April 28, 2014 BCC Research (http://www.bccresearch.com) reveals in its new report, DRUGS FOR TREATING SYSTEMIC LUPUS...

2014-03-17 12:27:32

--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, March 17, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of clinical studies with its lead compound RSLV-132. Resolve administered the first doses to humans of RSLV-132 its first-in-class targeted nuclease therapy designed to decrease the burden of circulating RNA-containing immune complexes in SLE patients. Ongoing studies are designed to evaluate the safety, tolerability,...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related